Muromonab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMuromonab
Drug Alias Name莫罗单抗-CD3Orthoclone OKT3ior-T3OKT-3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain inhibitors
TargetsT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsRejection of organ transplantationCNS Embryonal TumorKidney Neoplasms
Global Approved IndicationsRejection of organ transplantation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1992/09/14
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteOrtho Biotech Products LpUniversity Of Colorado Denver
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationCNS Embryonal TumorKidney Neoplasms

Other Information

ATC CodeL04AG01
Related LinksWikipediaDrugBankKEGG